Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Fig. 1

Duration of exposure and RECIST evaluation (FAS, N = 54). Footnote: ESCC esophageal squamous cell carcinoma, PD progressive disease, PR partial response, Q2W once every two weeks, QW once weekly, RECIST Response Evaluation Criteria In Solid Tumors, SCCHN squamous cell carcinoma of the head and neck, SD stable disease, UNK unknown

Back to article page
\